Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price gapped down prior to trading on Monday . The stock had previously closed at $47.37, but opened at $45.34. Zealand Pharma A/S shares last traded at $45.34, with a volume of 3,000 shares.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Finally, BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Zealand Pharma A/S currently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Stock Down 4.4%

The company has a debt-to-equity ratio of 0.02, a current ratio of 23.57 and a quick ratio of 23.57. The firm has a market cap of $3.24 billion, a price-to-earnings ratio of 3.31 and a beta of 0.87. The firm has a 50 day moving average price of $47.19 and a 200-day moving average price of $63.40.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The business had revenue of $10.79 million for the quarter, compared to analyst estimates of $19.69 million. As a group, equities analysts predict that Zealand Pharma A/S will post 2.51 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.